[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100573565":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":11,"centralContacts":32,"locations":11,"responsibleParty":38,"collaborators":11,"id":40,"slug":11,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":11,"eligibilityCriteria":45,"healthyVolunteers":41,"sex":46,"minAge":47,"maxAge":11,"enrollmentInfo":48,"targetDuration":11,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":11,"overallStatus":57,"whyStopped":11,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":11},{"fullName":5,"class":6},"Addpharma Inc.","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"AD-2281 + AD-2282","EXPERIMENTAL",null,[13,14],"Drug: AD-2281","Drug: AD-2282",{"label":16,"type":17,"description":11,"interventionNames":18},"AD-2281 + Placebo of AD-2282","ACTIVE_COMPARATOR",[13,19],"Drug: Placebo of AD-2282",[21,26,29],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":11},"DRUG","AD-2281","PO, Once daily, 8weeks",[9,16],{"type":22,"name":27,"description":24,"armGroupLabels":28,"otherNames":11},"AD-2282",[9],{"type":22,"name":30,"description":24,"armGroupLabels":31,"otherNames":11},"Placebo of AD-2282",[16],[33],{"name":34,"role":35,"phone":36,"phoneExt":11,"email":37},"JeongEun Park","CONTACT","+82-31-891-6989","parkje@addpharma.co.kr",{"type":39,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100573565",false,"NCT06747936","A Study to Evaluate the Efficacy and Safety of Co-administration of AD-2281 and AD-2282","A Randomized, Double-blind, Active-controlled, Multi-center, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combined Administration of AD-2281 and AD-2282 in Patients with Primary Hypercholesterolemia.","Inclusion Criteria:\n\n* Signed informed consent\n* Patients with Primary Hypercholesterolemia\n* Other inclusions applied\n\nExclusion Criteria:\n\n* Patients with Secondary Hypercholesterolemia\n* Other exclusions applied","ALL","19 Years",{"count":49,"type":50},110,"ESTIMATED","INTERVENTIONAL",[53],"PHASE3","The purpose of this study is to evaluate the efficacy and safetyof co-administration of AD-2281 and AD-2282 in patients with Primary Hypercholesterolemia",[56],"Primary Hypercholesterolemia","NOT_YET_RECRUITING","2025-02-02",{"date":60,"type":61},"2025-02-04","ACTUAL",{"date":63,"type":50},"2025-02",{"date":65,"type":50},"2026-12",{"name":5,"class":6}]